Suberoylanilide hydroxamic acid synergistically enhances the antitumor activity of etoposide in Ewing sarcoma cell lines

Anti-Cancer Drugs

Volumn 26, Issue 8, 2015, Pages 843-851

  Unland, Rebekka ^a   Clemens, Dagmar ^a   Heinicke, Ulrike ^c   Potratz, Jenny C ^a   Hotfilder, Marc ^a   Fulda, Simone ^c   Wardelmann, Eva ^b   Frühwald, Michael C ^a,d   Dirksen, Uta ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d Children's Hospital Augsburg   (Germany)

Author keywords

doxorubicin; etoposide; Ewing sarcoma; rapamycin; SAHA; topotecan

Indexed keywords

CASPASE 3; DOXORUBICIN; ETOPOSIDE; RAPAMYCIN; TOPOTECAN; VORINOSTAT; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHEMOSENSITIVITY; CLONOGENESIS; COLONY FORMATION; COMPARATIVE STUDY; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG POTENTIATION; ENZYME ACTIVITY; EWING SARCOMA CELL LINE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MTT ASSAY; PRIORITY JOURNAL; S PHASE CELL CYCLE CHECKPOINT; WESTERN BLOTTING; BONE TUMOR; DRUG EFFECTS; EWING SARCOMA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE NEOPLASMS; CELL PROLIFERATION; DRUG SYNERGISM; ETOPOSIDE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; SARCOMA, EWING;

EID: 84938823329     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000256     Document Type: Article

References (38)

1. Janknecht R. EWS-ETS oncoproteins: the linchpins of Ewing tumors. Gene 2005; 363:1-14.
2. Riggi N, Suva ML, Suva D, Cironi L, Provero P, Tercier S, et al. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res 2008; 68:2176-2185.
3. Kovar H, Aryee DN, Jug G, Henöckl C, Schemper M, Delattre O, et al. EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro. Cell Growth Differ 1996; 7:429-437.
4. Lessnick SL, Braun BS, Denny CT, May WA. Multiple domains mediate transformation by the Ewing's sarcoma EWS/FLI-1 fusion gene. Oncogene 1995; 10:423-431.
5. Dockhorn-Dworniczak B, Schafer KL, Dantcheva R, Blasius S, Winkelmann W, Strehl S, et al. Diagnostic value of the molecular genetic detection of the t(11;22) translocation in Ewing's tumours. Virchows Arch 1994; 425:107-112.
6. Sankar S, Theisen ER, Bearss J, Mulvihill T, Hoffman LM, Sorna V, et al. Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth. Clin Cancer Res 2014; 20:4584-4597.
7. Li Y, Li X, Fan G, Fukushi J, Matsumoto Y, Iwamoto Y, Zhu Y. Impairment of p53 acetylation by EWS-Fli1 chimeric protein in Ewing family tumors. Cancer Lett 2012; 320:14-22.
8. Best JD, Carey N. Epigenetic opportunities and challenges in cancer. Drug Discov Today 2010; 15 (1-2):65-70.
9. Burdach S, Plehm S, Unland R, Dirksen U, Borkhardt A, Staege MS, et al. Epigenetic maintenance of stemness and malignancy in peripheral neuroectodermal tumors by EZH2. Cell Cycle 2009; 8:1991-1996.
10. Li B, Carey M, Workman JL. The role of chromatin during transcription. Cell 2007; 128:707-719.
11. Kouzarides T. Chromatin modifications and their function. Cell 2007; 128:693-705.
12. Sonnemann J, Trommer N, Becker S,Wittig S, Grauel D, Palani CD, Beck JF. Histone deacetylase inhibitor-mediated sensitization to TRAIL-induced apoptosis in childhood malignancies is not associated with upregulation of TRAIL receptor expression, but with potentiated caspase-8 activation. Cancer Biol Ther 2012; 13:417-424.
13. Unland R, Kerl K, Schlosser S, Farwick N, Plagemann T, Lechtape B, et al. Epigenetic repression of the dopamine receptor D4 in pediatric tumors of the central nervous system. J Neurooncol 2014; 116:237-249.
14. Yin D, Ong JM, Hu J, Desmond JC, Kawamata N, Konda BM, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Clin Cancer Res 2007; 13:1045-1052.
15. Furchert SE, Lanvers-Kaminsky C, Junvers H, Jung M, Loidl A, Fridlrs MC. Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int J Cancer 2007; 120:1787-1794.
16. Dos Santos MP, de Farias CB, Roesler R, Brunetto AL, Abujamra AL. In vitro antitumor effect of sodium butyrate and zoledronic acid combined with traditional chemotherapeutic drugs: a paradigm of synergistic molecular targeting in the treatment of Ewing sarcoma. Oncol Rep 2014; 31:955-968.
17. Richon VM, Garcia-Vargas J, Hardwick JS. Development of vorinostat: current applications and future perspectives for cancer therapy. Cancer Lett 2009; 280:201-210.
18. Keshelava N, Houghton PJ, Morton CL, Lock RB, Carol H, Keir ST, et al. Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. Pediatr Blood Cancer 2009; 53:505-508.
19. Richardson PG, Mitsiades CS, Laubach JP, Hajek R, Spicka I, Dimopoulos MA, et al. Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leuk Res 2013; 37:829-837.
20. Pitts TM, Morrow M, Kaufman SA, Tentler JJ, Eckhardt SG. Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models. Mol Cancer Ther 2009; 8:342-349.
21. Ramalingam SS, Parise RA, Ramanathan RK, Lagattuta TF, Musguire LA, Stoller RG, et al. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res 2007; 13:3605-3610.
22. Dietrich CS 3rd, Greenberg VL, DeSimone CP, Modesitt SC, van Nagell JR, Craven R, Zimmer SG. Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines. Gynecol Oncol 2010; 116:126-130.
23. Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer 2011; 104:1828-1835.
24. Fouladi M, Park JR, Stewart CF, Gilbertson RJ, Schaiquevich P, Sun J, et al. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. J Clin Oncol 2010; 28:3623-3629.
25. Hummel TR, Wagner L, Ahern C, Fouladi M, Reid JM, McGovern RM, et al. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study. Pediatr Blood Cancer 2013; 60:1452-1457.
26. Muscal JA, Thompson PA, Horton TM, Ingle AM, Ahern CH, McGovern RM, et al. A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916). Pediatr Blood Cancer 2013; 60:390-395.
27. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55.
28. Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 1997; 57:3823-3829.
29. Laird PW. Cancer epigenetics. Hum Mol Genet 2005; 14:R65-R76.
30. Sonnemann J, Kumar KS, Heesch S, Müller C, Hartwig C, Maass M, et al. Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells. Int J Oncol 2006; 28:755-766.
31. Paulussen M, Bielack S, Jürgens H, Casali PG. ESMO Guidelines Working Group. Ewing's sarcoma of the bone: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (Suppl 4):140-142.
32. Womer RB, West DC, Krailo MD, Dickman PS, Pawel BR, Grier HE, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol 2012; 30:4148-4154.
33. Hunold A, Weddeling N, Paulussen M, Ranft A, Liebscher C, Jürgens H. Topotecan and cyclophosphamide in patients with refractory or relapsed ewing tumors. Pediatr Blood Cancer 2006; 47:795-800.
34. Mateo-Lozano S, Tirado OM, Notario V. Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation. Oncogene 2003; 22:9282-9287.
35. Zhao H, Rybak P, Dobrucki J, Traganos F, Darzynkiewicz Z. Relationship of DNA damage signaling to DNA replication following treatment with DNA topoisomerase inhibitors camptothecin/topotecan, mitoxantrone, or etoposide. Cytometry A 2012; 81:45-51.
36. Schonn I, Hennesen J, Dartsch DC. Ku70 and Rad51 vary in their importance for the repair of doxorubicin-versus etoposide-induced DNA damage. Apoptosis 2011; 16:359-369.
37. Schonn I, Hennesen J, Dartsch DC. Cellular responses to etoposide: cell death despite cell cycle arrest and repair of DNA damage. Apoptosis 2010; 15:162-172.
38. Häcker S, Karl S, Mader I, Cristofanon S, Schweitzer T, Krauss J, et al. Histone deacetylase inhibitors prime medulloblastoma cells for chemotherapy-induced apoptosis by enhancing p53-dependent Bax activation. Oncogene 2011; 30:2275-2281.